[1]陈香丽,魏政洪,臧玉柱,等.克拉屈滨、吉西他滨、阿糖胞苷和白消安联合预处理方案在恶性淋巴瘤自体造血干细胞移植治疗中的疗效和安全性[J].新乡医学院学报,2022,39(12):1139-1144.[doi:10.7683/xxyxyxb.2022.12.007]
　CHEN Xiangli,WEI Zhenghong,ZANG Yuzhu,et al.Efficacy and safety of combined pretreatment regimen of cladribine,gemcitabine,cytosine arabinoside and busulfan in autologous hematopoietic stem cell transplantation for malignant lymphoma[J].Journal of Xinxiang Medical University,2022,39(12):1139-1144.[doi:10.7683/xxyxyxb.2022.12.007]
点击复制

克拉屈滨、吉西他滨、阿糖胞苷和白消安联合预处理方案在恶性淋巴瘤自体造血干细胞移植治疗中的疗效和安全性
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年12
页码:
1139-1144
栏目:
临床研究
出版日期:
2022-12-05

文章信息/Info

Title:
Efficacy and safety of combined pretreatment regimen of cladribine,gemcitabine,cytosine arabinoside and busulfan in autologous hematopoietic stem cell transplantation for malignant lymphoma
作者:
陈香丽1; 2; 3; 魏政洪1; 3; 臧玉柱1; 2; 3; 张文荟1; 2; 3; 刘忠文1; 2; 3
（1.河南省人民医院血液内科，河南　郑州　450003；2.郑州大学人民医院血液内科，河南　郑州　450003；3.河南大学人民医院血液内科，河南　郑州　450003）
Author(s):
CHEN Xiangli1; 2; WEI Zhenghong1; ZANG Yuzhu1; 2; ZHANG Wenhui1; 2; LIU Zhongwen1; 2
（1.Department of Hematology, Henan Provincial People′s Hospital，Zhengzhou 450003，Henan Province，China；2.Department of Hematology,Zhengzhou University People′s Hospital,Zhengzhou 450003，Henan Province，China；3.Department of Hematology,Henan University People′s Hospital,Zhengzhou 450003，Henan Province，China）
关键词:
淋巴瘤; 自体造血干细胞移植; 预处理方案; 克拉屈滨; 吉西他滨; 阿糖胞苷; 白消安
Keywords:
lymphoma; autologous hematopoietic stem cell transplantation; pretreatment regimen; cladribine; gemcitabine; cytosine arabinoside; busulfan
分类号:
R733.1
DOI:
10.7683/xxyxyxb.2022.12.007
文献标志码:
A
摘要:
目的　探讨克拉屈滨、吉西他滨、阿糖胞苷、白消安（CLGAB）联合预处理方案在恶性淋巴瘤自体造血干细胞移植（ASCT）中的疗效和安全性。方法　采用前瞻性、同期临床对照试验，选择2020年1月至2021年12月于河南省人民医院血液科行ASCT的34例恶性淋巴瘤患者为研究对象，根据预处理方案将患者分为对照组（n=19）和观察组（n=15）。对照组患者采用卡莫司汀/苯达莫司汀/司莫司汀、依托泊苷、阿糖胞苷、美法仑联合方案预处理，观察组患者采用CLGAB方案预处理。比较2种预处理方案对肿瘤细胞的杀伤作用、不良反应、造血重建效果、移植后疾病缓解及患者生存情况等。结果　2组采集到的单个核细胞值比较差异无统计学意义（t=0.977，P>0.05）。2组采集到的CD34+细胞水平比较差异无统计学意义（P>0.05）。2组患者预处理后均达到Ⅳ度骨髓抑制，观察组患者预处理后达Ⅳ度骨髓抑制时间显著短于对照组（P<0.05）。观察组患者中性粒细胞和血小板（PLT）植入时间显著早于对照组（P<0.05）；观察组患者移植期间应用血小板生成素时间显著短于对照组（P<0.05）。2组患者的PLT最低值、粒细胞缺少持续时间、应用粒细胞集落刺激因子时间、输注PLT数量及输注红细胞数量比较差异无统计学意义（P>0.05）。2组患者恶心/呕吐、发热、腹泻、口腔黏膜炎、肝损伤、低血钾、出血及心脏毒性不良反应发生率比较差异无统计学意义（P>0.05）；2组患者的Ⅲ/Ⅳ级严重不良反应发生率较低，均未发生肝静脉闭塞性疾病及移植相关死亡。移植后3个月，观察组患者获得完全缓解（CR） 15例（100.0%），早期总反应率（ORR）为100.0%（15/15）；对照组患者获得CR 15例（78.9%），部分缓解 1例（5.3%），疾病稳定1例（5.3%），疾病进展2例（10.5%），早期ORR为84.2%（16/19）；2组患者早期ORR比较差异无统计学意义（P>0.05）。观察组无复发和死亡病例，患者的PFS率和OS率均为100.0%。对照组3例患者复发，1例因疾病进展死亡， 患者的PFS率和OS率分别为84.2%、94.7%。2组患者的PFS率、OS率比较差异无统计学意义（P>0.05）。结论　CLGAB预处理方案杀伤肿瘤细胞效果理想且预处理毒性可耐受，造血重建较快，早期疗效好，复发率低，是恶性淋巴瘤ASCT可行、有效的预处理方案。
Abstract:
Objective　To investigate the efficacy and safety of the combined pretreatment regimen of cladribine,gemcitabine,cytosine arabinoside and busulfan (CLGAB) in autologous hematopoietic stem cell transplantation (ASCT) for malignant lymphoma.Methods　A prospective,concurrent clinical controlled trial was conducted，a total of 34 malignant lymphoma patients who underwent ASCT in the Department of Hematology,Henan Provincial People′s Hospital from January 2020 to December 2021 were selected as the study subjects,and the patients were divided into control group (n=19) and observation group (n=15) according to the pretreatment regimen.The patients in the control group were pretreated with the regimen of carmustine/bendamostine/simustine,etoposide,cytosine arabinoside,and mephalon,the patients in the observation group were pretreated with the regimen of CLGAB.The killing effect on tumor cells,adverse reaction of pretreatment,hematopoiesis reconstruction,disease remission and survival of patients between the two regimens were compared.Results　 There was no significant difference in mononuclear cell values of patients between the two groups (t=0.977,P>0.05).There was no significant difference in CD34+cells level of patients between the two groups (P>0.05).The patients in both groups all reached Ⅳ degree of bone marrow suppression after pretreatment,and the time of reaching Ⅳ degree of bone marrow suppression after pretreatment of patients in the observation group was significantly shorter than that in the control group (P<0.05).The implantation time of neutrophils and platelets (PLT) of patients in the observation group were significantly earlier than those in the control group (P<0.05).The time of thrombopoietin application during transplantation of patients in the observation group was significantly less than that in the control group (P<0.05).There was no significant difference in the minimum value of PLT,duration of granulocyte deficiency,time of granulocyte colony-stimulating factor application,number of PLT transfusions and number of red blood cells transfused for patients between the two groups (P>0.05).There was no significant difference in the incidences of nausea/vomiting,fever,diarrhea,oral mucositis,liver injury,hypokalemia,bleeding and adverse cardiac reactions of patients between the two groups (P>0.05);the incidences of Class Ⅲ/Ⅳ serious adverse reactions of patients in the two groups were low,and there was no hepatic vein occlusive disease and transplantation related mortality.Three months after transplantation,complete remission（CR）was obtained in 15 patients (100.0%),and the early overall response rate （ORR） was 100.0% (15/15) in the observation group;in the control group,CR was obtained in 15 cases (78.9%),partial remission in 1 case (5.3%),stable disease in 1 case (5.3%),progressive disease in 2 cases (10.5%),and the early ORR was 84.2% (16/19);there was no significant difference in early ORR of patients between the two groups (P>0.05).There was no recurrence or death in the observation group,and the progress free survival (PFS) rate and overall survival (OS) rate of patients were both 100.0%.In the control group,3 patients relapsed and 1 patient died due to disease progression,the PFS rate and OS rate of patients were 84.2% and 94.7% respectively.There was no significant difference in the PFS rate and OS rate of patients between the two groups (P>0.05).Conclusion　CLGAB regimen has ideal myeloablative effect,tolerable pretreatment toxicity,rapid hematopoietic reconstruction,good early efficacy and low recurrence rate,it is a feasible and effective pretreatment regimen for ASCT of lymphoma.

参考文献/References:

［1］　郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析［J］.中华肿瘤杂志,2019,41(1):19-28.
ZHENG R S,SUN K S,ZHANG S W,et al.Report of cancer epidemiology in China,2015［J］.Chin J Oncol,2019,41(1):19-28.
［2］　ZENG H,CHEN W,ZHENG R,et al.Changing cancer survival in China during 2003-15:a pooled analysis of 17 population-based cancer registries［J］.Lancet Glob Health,2018,6(5):e555-e567.
［3］　WULLENKORD R,BERNING P,NIEMANN A L,et al.The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas:real-world data from a retrospective single-center analysis［J］.Ann Hematol,2021,100(11):2733-2744.
［4］　ZOELLNER A K,UNTERHALT M,STILGENBAUER S,et al.Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission:a post-hoc analysis of an open-label,multicentre,randomised,phase 3 trial［J］.Lancet Haematol,2021,8(9):e648-e657.
［5］　中国抗癌协会血液肿瘤专业委员会,中华医学会血液学分会白血病淋巴瘤学组,中国临床肿瘤学会抗淋巴瘤联盟.造血干细胞移植治疗淋巴瘤中国专家共识(2018版)［J］.中华肿瘤杂志,2018,40(12):927-934.
HEMATOLOGY ONCOLOGY COMMITTEE OF CHINA ANTI-CANCER ASSOCIATION,LEUKEMIA & LYMPHOMA GROUP,SOCIETY OF HEMATOLOGY AT CHINESE MEDICAL ASSOCIATION,CHINESE UNION OF LYMPHOMA RESEARCH,CHINESE SOCIETY OF CLINICAL ONCOLOGY.The Chinese expert consensus on hematopoietic stem cell transplantation for malignant lymphoma(2018)［J］.Chin J Oncol,2018,40(12):927-934.
［6］　GIRALT S,COSTA L,SCHRIBER J,et al.Optimizing autologous stem cell mobilization strategies to improve patient outcomes:consensus guidelines and recommendations［J］.Biol Blood Marrow Transplant,2014,20(3):295-308.
［7］　CHEN Y B,LANE A A,LOGAN B,et al.Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation［J］.Biol Blood Marrow Transplant,2015,21(6):1046-1053.
［8］　SHI Y,LIU P,ZHOU S,et al.Comparison of CBV,BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma:efficacy and toxicity［J］.Asia Pac J Clin Oncol,2017,13(5):e423-e429.
［9］　XU L,JIAO J,SUN X,et al.Cladribine induces ATF4 mediated apoptosis and synergizes with SAHA in diffuse large B-cell lymphoma cells［J］.Int J Med Sci,2020,17(10):1375-1384.
［10］　JI J,LIU Z,KUANG P,et al.A new conditioning regimen with chidamide,cladribine,gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin′s lymphomas［J］.In J Cancer,2021,149(12):2075-2082.
［11］　JI J,VALDEZ B C,LI Y,et al.Cladribine,gemcitabine,busulfan,and SAHA combination as a potential pretransplant conditioning regimen for lymphomas:a preclinical study［J］.Exp Hematol,2016,44(6):458-465.
［12］　周笑,杨隽,蔡宇,等.阿糖胞苷联合氟达拉滨或克拉屈滨预处理的异基因造血干细胞移植治疗72例未缓解急性髓系白血病的临床分析［J］.临床血液学杂志,2020,33(7):469-474.
ZHOU X,YANG J,CAI Y,et al.Conditioning regimens including cytarabine plus fludarabine or cladribine may improve the outcomes of allogeneic hematopoietic stem cell transplantation for 72 patients with refractory/relapsed acute myeloid leukemia［J］.J Clin Hematol,2020,33(7):469-474.
［13］　SWERDLOW S H,CAMPO E,HARRIS N L.WHO classification of tumours of haematopoietic and lymphoid tissues［M］.4th ed.Lyon:LARC Press,2017.
［14］　CHUNG A E,SHOENBILL K,MITCHELL S A,et al.Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute′s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)［J］.J Am Med Inform Assoc,2019,26(4):276-285.
［15］　平措卓嘎,左旭盈,王剑利,等.化疗序贯自体造血干细胞移植治疗淋巴瘤的疗效评价及影响因素分析［J］.现代肿瘤医学,2022,30(3):509-513.
PINGCUO Z G,ZUO X Y,WANG J L,et al.Efficacy evaluation and influencing factors of autologous hematopoietic stem cell transplantation following chemotherapy in the treatment of lymphoma［J］.Mod Oncol,2022,30(3):509-513.
［16］　王清松,王凌云,王萍.恶性淋巴瘤患者自体造血干细胞移植治疗后的生存及预后因素分析［J］.实用癌症杂志,2020,35(5):756-759.
WANG Q S,WANG L Y,WANG P.Analysis of survival and prognosis factors in patients with malignant lymphoma after autologous hematopoietic stem cell transplantation［J］.Pract J Cancer,2020,35(5):756-759.
［17］　曹琳琳,丁凯阳,宋浩,等.自体造血干细胞移植治疗恶性淋巴瘤的疗效及影响因素［J］.中国组织工程研究,2021,25(13):1993-1998.
CAO L L,DING K Y,SONG H,et al.Efficacy and influencing factors of autologous hematopoietic stem cell transplantation in the treatment of malignant lymphoma［J］.Chin J Tissue Eng Res,2021,25(13):1993-1998.
［18］　CHANTEPIE S P,GARCIAZ S,TCHERNONOG E,et al.Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT):results of a French multicenter study of 474 patients from Lymphoma Study Association (LYSA) centers［J］.Am J Hematol,2018,93(6):729-735.
［19］　SINGER S,SHARMA N,DEAN R,et al.BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin′s lymphomas［J］.Bone Marrow Transplant,2019,54(10):1553-1561.
［20］　姚囡囡,林莉莉,黄珊,等.312例吉西他滨的不良反应分析［J］.药学实践杂志,2020,38(2):174-178.
YAO N N,LIN L L,HUANG S,et al.Analysis of adverse reactions in 312 cases of gemcitabine［J］.J Pharm Pract,2020,38(2):174-178.

相似文献/References:

[1]姜黄,杨广英,王玉香.胃肠道黏膜相关淋巴瘤27 例临床病理分析[J].新乡医学院学报,2010,27(06):606.
[2]王晓,常保萍,王瑞丽,等.蒽环类药物治疗弥漫大B细胞淋巴瘤中脑钠肽水平检测的临床意义[J].新乡医学院学报,2012,29(11):859.
[3]董蕾,关晨阳,张莹,等.症状群信息化管理平台的建立及其在接受嵌合抗原受体T细胞免疫治疗淋巴瘤患者中的应用效果[J].新乡医学院学报,2023,40(2):169.[doi:10.7683/xxyxyxb.2023.02.014]
　DONG Lei,GUAN Chenyang,ZHANG Ying,et al.Establishment of symptom cluster information management platform and its application effect in lymphoma patients receiving chimeric antigen receptor T cell immunotherapy[J].Journal of Xinxiang Medical University,2023,40(12):169.[doi:10.7683/xxyxyxb.2023.02.014]

更新日期/Last Update: 2022-12-05